News

“Just weeks ago we received clearance from the US Treasury Department to extend our US clinical program for nimotuzumab, permitting us to conduct trials in any cancer indication.

Active Biotech’s prostate cancer project TASQ, where TASQ was studied as a single agent in patients with castration-resistant prostate cancer, was published in British Journal of Cancer. Two

Novartis has received a positive opinion recommending EU approval of QAB149 for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). The company said that

Total operating expenses decreased $107,869 or 2.2% vs. the prior year. Operating loss for the fiscal year was $349,490 vs. an operating loss of$602,279 for the prior year.

The new data from the phase III PLATO study showed that AstraZeneca’s BRILINTA (ticagrelor) provided reduction of cardiovascular (CV) events than clopidogrel (9.02% vs 10.65%, p=0.0025 a 16%

Boston Scientific has declared a two-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and

Repligen has announced the publication of research that identifies histone deacetylase 3 (HDAC 3) as an enzyme target for therapeutic intervention in Friedreich’s ataxia. Reportedly, the research findings

The Drugs Controller General of India (DCGI) has issued guidelines for grant of WHO-GMP Certificate of Pharmaceutical Product (CoPP) by the CDSCO offices, starting October 1. DCGI has

Aesica’s Cramlington, UK site has been recently granted a Home Office licence to allow manufacture and supply of substances listed in Schedule 2 of the Misuse of Drugs